share_log

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

Cantor Fitzgerald继续对安进保持增持评级,目标价为405美元,预计2024年营业收入为332亿美元;强调管道风险以及AMG-133一期试验中出现的-4% BMD损失。
Benzinga ·  2024/11/13 03:21  · 评级/大行评级

Cantor Fitzgerald Maintains Overweight Rating On Amgen With $405 Price Target, Projecting $33.2B Revenue In 2024; Highlights Pipeline Risks And -4% BMD Loss In AMG-133 Phase 1 Trial

康特菲茨杰(Cantor Fitzgerald)维持对安进(Amgen)的增持评级,目标价为405美元,预计2024年营业收入达到332亿美元;强调管道风险和AMG-133第1期试验中4%骨密度损失。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发